Drug Trial Radar · NCT05343715
PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV Infusion
Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Oct 23, 2021
Primary completion
Mar 6, 2022
Study completion Apr 17, 2022
Sponsor
- Lead sponsor
- Bio Sidus SAIndustry
- Sponsor type
- Industry
- First posted
- Apr 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Pharmacokinetic/Pharmacodynamic Study of 2 agalsidase beta Formulations in Single Dose Administered to Healthy Volunteers as intravenous infusion, at a concentration of 1 mg/kg
Conditions
- Fabry Disease
Interventions
Agalsidase beta from Biosidus 1 mg/kgBiological
Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
Fabrazyme (agalsidase beta) 1 mg/kgBiological
Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Serum Concentration of Agalsidase Beta (Cmax)Time frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
- Area Under the Curve of Serum Concentration Between Times 0 and 12 Hours of Agalsidase BetaTime frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
- Time at Which Maximum Serum Concentration of Agalsidase Beta is Observed (Tmax)Time frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
- Area Under the Curve of Serum Concentration, Resulting From the Extrapolation From Time 0 to Infinite TimeTime frame: 0, 1, 3, 5, 5.5, 6, 7, 8, 10 and 12 hours from the beginning of the infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sanatorio Nuestra Señora del Pilar
Ciudadela, Buenos Aires, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.